fashion -WSS

fashion

author：explore 2025-09-27 17:03:12 - browse：89313

Exterior photo of UnitedHealth Group building — UnitedHealth Group is attempting to buy Amedisys for $3.3 billion. Courtesy UnitedHealth Group

There’s now a two-party showdown for one of the largest home health companies in the country.

UnitedHealth Group and its Optum division on Monday formally proposed to buy Amedisys for $100 per share, or about $3.3 billion.

The offer comes a few weeks after Option Care Health proposed a $3.6 billion takeover. However, Option Care’s deal is an all-stock transaction, whereas UnitedHealth would pay all cash — a potentially more attractive offer for Amedisys shareholders who want a more immediate payout that isn’t tied to the unpredictability of another company’s stock price. Option Care’s offer is technically worth closer to $2.8 billion now, due to the drop in Option Care’s stock price since the merger was announced. Amedisys is recommending shareholders vote in favor of the deal with Option Care.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Readout Newsletter: Bayer study halts, Carmot to IPO, and more

WSS

World's first CRISPR

FDA's Woodcock to retire early next year

Surge of respiratory disease in China has likely explanation

Congress must reauthorize a committee to support older Americans

Anthos stroke drug appears safer than common blood thinner

Why medical students are struggling with mental health

leisure time

fashion

knowledge

Jerome Adams on the need for new antivirals for Covid

World's first CRISPR

Continuity nursing helped my family in our darkest PICU moments

FDA approves Moderna’s RSV vaccine, its second licensed product

State Dept. review finds Biden bears some blame for Afghanistan failures

Data don't support strong claims for Covid

The cancer drug shortage isn’t new — and neither are the solutions

Eli Lilly’s Zepbound improved liver scarring in mid

At least 13 dead in Texas as scorching temps continue

Elevance PBM president out as customers face prescription chaos

Wikipedia

FDA approves Moderna’s RSV vaccine, its second licensed product

CRISPR pioneers react to Casgevy, first gene

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

PBM reforms clear House panel

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

entertainment

entertainment

leisure time

entertainment